Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.13% | -8.42% | -13.01% | -6.78% | -8.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.13% | -8.42% | -13.01% | -6.78% | -8.49% |
| Cost of Revenue | 22.57% | -0.07% | -15.39% | -16.22% | -16.64% |
| Gross Profit | 1.32% | -8.75% | -12.91% | -6.38% | -8.14% |
| SG&A Expenses | -0.04% | 0.37% | -4.89% | -2.90% | 8.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.61% | 0.18% | -5.11% | -5.00% | 3.15% |
| Operating Income | 15.97% | -50.60% | -49.41% | -15.53% | -54.92% |
| Income Before Tax | 119.62% | 116.40% | 121.73% | 130.17% | -451.03% |
| Income Tax Expenses | -40.53% | -66.27% | -59.20% | -37.52% | -36.43% |
| Earnings from Continuing Operations | 114.12% | 111.06% | 114.66% | 120.94% | -742.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.19% | 34.49% | 43.60% | 22.00% | 38.62% |
| Net Income | 107.49% | 104.84% | 108.27% | 113.00% | -2,033.69% |
| EBIT | 15.97% | -50.60% | -49.41% | -15.53% | -54.92% |
| EBITDA | 21.72% | -43.01% | -44.61% | -12.49% | -51.06% |
| EPS Basic | 105.99% | 104.02% | 106.98% | 111.36% | -1,827.29% |
| Normalized Basic EPS | 282.33% | 22.86% | 213.61% | 783.44% | -130.89% |
| EPS Diluted | 102.83% | 101.24% | 101.55% | 103.66% | -3,080.67% |
| Normalized Diluted EPS | 190.79% | 631.91% | 598.00% | 322.16% | -172.04% |
| Average Basic Shares Outstanding | 7.76% | 13.85% | 21.38% | 29.26% | 28.55% |
| Average Diluted Shares Outstanding | 3.84% | 10.39% | 17.96% | 27.19% | 26.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |